Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Bone Therapeutics  /  Forum Bone Therapeutics geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel BIOSENIC BRU:BIOS.BL, BE0974280126

  • 0,021 16 apr 2024 13:34
  • -0,001 (-3,60%) Dagrange 0,020 - 0,022
  • 782.766 Gem. (3M) 1,2M

Forum Bone Therapeutics geopend

319 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste | Omlaag ↓
  5. [verwijderd] 26 juni 2017 07:47
    Kan een mooie dag worden:

    Het Europees Octrooibureau heeft Bone Therapeutics laten weten dat het van plan is om het allogene botteltherapieplatform van het biotechbedrijf te patenteren. Dit maakte Bone Therapeutics maandag voorbeurs bekend.Nadat het patent is toegekend, worden zowel de vervaardigingsmethoden als het celtype dat Bone Therapeutics gebruikt voor het platform beschermd tot 2029. Het biotechbedrijf hoopt dat het patent in "diverse landen" in de Europese Unie van kracht wordt.
  6. +brammeke 3 juli 2017 23:36
    Steve Swinson elected as Chairman of the Board of Bone Therapeutics Dirk Dembski appointed as Non-Executive Director, bolstering the Board with additional orthopaedic and biotechnology expertise Michel Helbig to remain as a Non-Executive Director Gosselies, Belgium, 3 July 2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that Steve Swinson has been elected as Chairman of the Board of Directors. He will replace Michel Helbig, who has stood down as Chairman but will continue as a Non-Executive Director. Bone Therapeutics has also continued to strengthen its Board with the appointment of Dirk Dembski as a Non-Executive Director. The appointment of Dirk, a seasoned executive with expertise in orthopaedics and biotechnology and experience in sales, marketing, business development and medical education for global life sciences companies, complements the recent appointments of Steve Swinson and Damian Marron, who both joined the Bone Therapeutics Board in May. These appointments significantly increase the breadth of specialist orthopaedic and regenerative therapy expertise at the Company and will help support the new management team, led by Chief Executive Thomas Lienard. Steve Swinson has served in a number of senior roles in orthopaedic medical technology and electronics, including general management, senior strategy, sales, marketing and commercial operation positions at Medtronic. At Medtronic, he led the Spine and Biologics division for Canada and Western Europe, and was Vice President and General Manager for the international spine division. with substantial revenue responsibility. In a 30-year international business career covering Asia, US, Europe and Africa, he has also held senior positions in the diagnostic and medical divisions of General Electric and Hewlett Packard. Steve has a PhD in electrical engineering from the University of Manchester and a MBA from the University of Chicago. Steve Swinson is currently chairman of the board of Vexim, a medical device company specializing in minimally invasive treatment of vertebral fractures and is also on the board of directors of Acteon Group, a leader in dental equipment and imaging products. Dirk Dembski has held a variety of roles in biotechnology, orthopaedics and medical companies and has built and driven global sales and marketing operations and served in business development positions. He is currently serving as Managing Director of bricon Group, the German business unit of Naton Medical Group, one of China's largest Medtech companies, where he completed several acquisitions and drives the international business. He also worked as Vice President of Sales, Marketing and Business Development at Olympus Biotech for EMEA, Asia Pacific and Latin America, where he successfully marketed a portfolio of bone growth factors, cell technologies and innovative biomaterials. Dirk has also worked as director of sales and marketing for Small Bone Innovations, a bone medical technology company which was acquired by Stryker. Marc Nolet de Brauwere van Steeland, stepped down as a Non-Executive Director on 30 June having served on the Bone Therapeutics Board since 2015. Thomas Lienard, Chief Executive of Bone Therapeutics, said: " With the election of Steve Swinson as Chairman, and the appointments of Dirk Dembski and Damian Marron, we have a world-leading Board to support Bone Therapeutics as we approach critical inflection points for our allogeneic cell therapy platform. Our new Board members bring a unique and highly complementary set of skills and expertise in the development and commercialisation of orthopaedic and cell therapy products. I would like to welcome Steve and our other new Board members and also to thank Michel Helbig for his four years of service to Bone Therapeutics. Michel has provided calm and judicious guidance to the company through key strategic developments, including helping to steer the Company through its 2015 Initial Public Offering. Michel was instrumental in building the strong management team that will prove critical as the Company advances its allogeneic cell therapy platform towards commercialization, as well as in the development of the board since IPO. He has also played a key role more recently in recruiting top-level board members with strong international experience in the field in which Bone Therapeutics operates. We are delighted that he will remain on the Board to provide continued support. " Steve Swinson, Chairman of Bone Therapeutics, commented: " I feel excited and privileged to be taking the role of Chairman at Bone Therapeutics. This is the most advanced Company in regenerative therapies for bone diseases which I believe has the potential to transform medical practice in this field. I hope to be able to apply my deep experience in medical technology to support Thomas Lienard and his team, alongside my colleagues on the Board, as we move this key product platform towards commercialization. " Dirk Dembski added: " I feel my previous experience and expertise wil be invaluable to Bone Therapeutics as it develops into a commercially ready company. I look forward to working with Steve and the rest of the Board to help steer the company as it brings its exciting technologies to market. " About Bone Therapeutics Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation. Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery. Our primary clinical focus is ALLOB ® , an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB ® , obtained from patient`s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures

    Bron: Trivano www.trivano.com/aandeel/bone-therapeu...
  10. +brammeke 30 augustus 2017 14:06
    Beursblik: KBC Securities start volgen Bone Therapeutics met Accumuleren advies
    Gepubliceerd op 30 aug 2017 om 09:11 |

    Bone Therapeutics (13:37)
    EUR 9,701 +0,151 (+1,58%)

    (ABM FN) KBC Securities is gestart met het volgen van Bone Therapeutics met een Accumuleren advies en koersdoel van 10,50 euro. Dit bleek uit een note van de analisten van het beurshuis woensdag voorbeurs.
    Analisten Sandra Cauwenberghs en Lenny Van Steenhuyse zijn positief over het biotechbedrijf op korte termijn. In het derde kwartaal zien ze testresultaten als mogelijke triggers voor het aandeel. Bij interimdata werden reeds positieve signalen gezien voor het middel ALLOB, aldus de analisten.
    Dit laatste product is volgens KBC Securities ook het belangrijkste element in de portfolio van Bone Therapeutics.
    Verder zijn de analisten positief over de transformatie van het bedrijf van een autologe benadering naar een allogeneïsche, welke meer commercieel potentieel biedt.
    De kaspositie aan het eind van het eerste kwartaal bedroeg 16,5 miljoen euro. Volgens KBC Securities zal er genoeg financiële ruimte zijn tot het tweede kwartaal van 2018 met een cashburn van 15 miljoen euro voor dit jaar.
    Tegen 2019 verwacht KBC Securities een omzet van 15 miljoen euro.
    Het aandeel van Bone Therapeutics noteerde woensdag kort na opening 1,3 procent hoger op 9,67 euro.
  14. +brammeke 22 september 2017 09:46
    Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in JapanAsahi Kasei obtains exclusive license for the development and commercialisation of PREOB® in JapanOption to extend license to other Asian countriesGosselies, Belgium, 22 September 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it has signed an exclusive, royalty-bearing license agreement with one of Japan’s leading industrial companies, Asahi Kasei Corporation (Tokyo: 3407). The license agreement covers the development and commercialisation of Bone Therapeutics’ autologous bone cell therapy product, PREOB®, in Japan. Under the terms of the agreement, Asahi Kasei will obtain exclusive rights to develop, register and commercialise PREOB® for the treatment of osteonecrosis of the hip with the potential for other orthopaedic and bone applications in Japan. Bone Therapeutics will share its patented proprietary manufacturing expertise for the expansion and differentiation of stem cells into bone-forming cells in preparation for continued clinical development by Asahi Kasei in Japan. In addition, Bone Therapeutics has also granted Asahi Kasei an option to negotiate an exclusive license for the development and commercialization of PREOB® in Korea, China and Taiwan. Bone Therapeutics will receive an upfront payment of €1.7 million from Asahi Kasei and is eligible to receive up to €7.5 million from development and commercial milestone payments, as well as tiered royalties based on annual net sales of PREOB® in Japan. Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented: “This agreement is an important additional validator of our innovative regenerative technology in the field of orthopaedics and bone diseases and of its global, commercial potential. With its world-class research and development capabilities, its strong network and specific knowledge of the Japanese market, we believe Asahi Kasei is the ideal partner to develop and commercialize PREOB® in Japan and bring this promising therapy to patients in Asia. We look forward to working with the team at Asahi Kasei as we bring our platform closer towards commercialisation.” Hideki Kobori, President & Representative Director of Asahi Kasei Corporation, said: “We are delighted to be collaborating with Bone Therapeutics to develop and commercialize its unique autologous cell therapy product, PREOB®, in Japan. The field of orthopaedics is a major area of focus for Asahi Kasei and we believe PREOB® has the potential to add significant value to our current pipeline and has the potential to be a first-in-class treatment for patients suffering from debilitating bone conditions, such as osteonecrosis of the hip.”
  17. +brammeke 22 september 2017 15:45
    quote:

    nightrider schreef op 22 september 2017 13:30:

    De stijging kon zich blijkbaar niet doortrekken, was anders bij kiadis, daar skyhigh, was hier beter ook zo geweest. Komt misschien nog.
    Niet misschien! Wanneer? De echte doorbraak a la Galapagos verwacht ik binnen enkele jaren.
319 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!